Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)

  • APEX Investigators
  • , I. Stukena (Member of the Working Group)

Research output: Contribution to journalArticlepeer-review

61 Citations (Scopus)
344 Downloads (Pure)
Original languageEnglish
Pages (from-to)648-655
JournalCirculation
Volume135
Issue number7
DOIs
Publication statusPublished - 14 Feb 2017
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords*

  • anticoagulants
  • cardiology
  • cardiovascular diseases
  • intracranial hemorrhages
  • stroke
  • thrombosis

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Cite this